Global Endocrine Testing Market: Industry Analysis and Forecast (2019-2027) – By Test, Technology, End Use and Region.

Global Endocrine Testing Market was valued US$ XX Bn in 2019 and is expected to reach XX Bn by 2027, at a CAGR of 8.00% during a forecast period. The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. The endocrine system plays a vital role in reproduction, growth and sexual development, retorts to injury and stress, body energy levels, bone and muscle strength, and also internal balance of the body. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis. The growing incidence of hormonal imbalances in individuals is one of the key drivers in the global endocrine testing market. The changing lifestyles, growing stress, and unhealthy food habits result in improved obesity and disturbed hormonal changes are some of the driving factors behind the growth in the global endocrine testing market. The software has been designed to accomplish the workflow in the laboratories. Newer mobile apps have been presented wherein a patient can be reminded about his appointment or test, and he will be able to contact a physician. These advancements in technology are projected to propel the global endocrine testing market growth over the forecast period. On the other hand, the high cost of technology is projected to be the key restraint for the growth of the global endocrine testing market. Furthermore, an increase in the investment in research and technology is measured as a major opportunity for the growth of the global endocrine testing market. The thyroid-stimulating hormone (TSH) test is expected to share significant growth in the global endocrine testing market. The significant growth in the market is attributed to the growing incidences of TSH-related disorders and the rising awareness regarding the correlation between variations in the thyroid hormone levels and cardiovascular disorders. Furthermore, the Insulin test is expected to grow at a XX % rate of CAGR during the forecast period. The considerable rise in the diabetic population and the rising awareness about diagnosis are expected to contribute towards the demand for an insulin test. The tandem mass spectrometry is estimated to hold a dominant position in the global endocrine testing market followed by sensor technology segement. The growing use of tandem mass spectrometry in combination with liquid chromatography, which also helps in overcoming the challenges associated with traditional techniques is expected to increase the demand for tandem mass spectrometry. On the other hand, sensor technology is projected to grow at a XX % rate of CAGR during the forecast period owing to the increasing use of biosensors in glucose monitoring for diabetes which is used on routine basis by the individuals to monitor their blood sugar level. Geographically, North America region is estimated to contribute a significant share in the global endocrine testing market. Growing incidence of several types of endocrine diseases, rapid adoption of novel testing techniques supported by regulatory infrastructure and positive recompense scenario are the some of the prominent factors behind the growth in the global endocrine testing market. The objective of the report is to present a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, industry-validated market data and projections with a suitable set of assumptions and methodology. The report also helps in understanding dynamics, structure by analysing the market segments and, project the global endocrine testing market. The report also provides a clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the global endocrine testing market. The report also provides PEST analysis, PORTER’s analysis, SWOT analysis to address the question of shareholders in arranging the efforts and investment in the near future to a particular market segment.

Scope of the Report for Global Endocrine Testing Market

Global Endocrine Testing Market, By Test

• Follicle stimulating hormone (FSH) • Human Chorionic Gonadotropin (hCG) • Thyroid Stimulating Hormone (TSH) • Dehydroepiandrosterone sulphate (DHEAS) • Prolactin • Progesterone • Insulin • Cortisol • Testosterone • Estradiol (E2) • Luteinizing Hormone (LH)

Global Endocrine Testing Market, By Technology

• Immunoassay • Clinical Chemistry • Monoclonal and Polyclonal Antibody • Sensor technology • Tandem Mass Spectroscopy

Global Endocrine Testing Market, By End User

• Hospitals • Physician Offices • Health Care Centers • Commercial Laboratories

Global Endocrine Testing Market, By Region

• North America • Europe • Asia Pacific • Middle East & Africa • South America

Key players operating in Global Endocrine Testing Market

• Thermo Fisher Scientific, Inc. • Quest Technology • Biomedical Technologies. • Sysmex Corporation • Abbott Laboratories • AB Sciex Pte. Ltd. • Agilent Technologies • Siemens Healthcare • Ortho Clinical Technology • BioMerieux SA • Bio-Rad Laboratories • DiaSorin S.p.A • F. Hoffmann-La Roche Ltd. • Laboratory Corporation of America Holdings • Hoffmann-La Roche Ltd. • LabCorp • Alfa Aesar • Laboratory Corporation of America Holdings (LabCorp) • Beckman Coulter Inc • Teleflex Inc

Global Endocrine Testing Market

1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Endocrine Testing Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Endocrine Testing Market Analysis and Forecast 6.1. Global Endocrine Testing Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Endocrine Testing Market Analysis and Forecast, by Test 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Endocrine Testing Market Value Share Analysis, by Test 7.4. Global Endocrine Testing Market Size (US$ Bn) Forecast, by Test 7.5. Global Endocrine Testing Market Analysis, by Test 7.6. Global Endocrine Testing Market Attractiveness Analysis, by Test 8. Global Endocrine Testing Market Analysis and Forecast, by Technology 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Endocrine Testing Market Value Share Analysis, by Technology 8.4. Global Endocrine Testing Market Size (US$ Bn) Forecast, by Technology 8.5. Global Endocrine Testing Market Analysis, by Technology 8.6. Global Endocrine Testing Market Attractiveness Analysis, by Technology 9. Global Endocrine Testing Market Analysis and Forecast, by End User 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Endocrine Testing Market Value Share Analysis, by End User 9.4. Global Endocrine Testing Market Size (US$ Bn) Forecast, by End User 9.5. Global Endocrine Testing Market Analysis, by End User 9.6. Global Endocrine Testing Market Attractiveness Analysis, by End User 10. Global Endocrine Testing Market Analysis, by Region 10.1. Global Endocrine Testing Market Value Share Analysis, by Region 10.2. Global Endocrine Testing Market Size (US$ Bn) Forecast, by Region 10.3. Global Endocrine Testing Market Attractiveness Analysis, by Region 11. North America Endocrine Testing Market Analysis 11.1. Key Findings 11.2. North America Endocrine Testing Market Overview 11.3. North America Endocrine Testing Market Value Share Analysis, by Test 11.4. North America Endocrine Testing Market Forecast, by Test 11.4.1. Follicle stimulating hormone (FSH) 11.4.2. Human Chorionic Gonadotropin (hCG) 11.4.3. Thyroid Stimulating Hormone (TSH) 11.4.4. Dehydroepiandrosterone sulphate (DHEAS) 11.4.5. Prolactin 11.4.6. Progesterone 11.4.7. Insulin 11.4.8. Cortisol 11.4.9. Testosterone 11.4.10. Estradiol (E2) 11.4.11. Luteinizing Hormone (LH) 11.5. North America Endocrine Testing Market Value Share Analysis, by Technology 11.6. North America Endocrine Testing Market Forecast, by Technology 11.6.1. Immunoassay 11.6.2. Clinical Chemistry 11.6.3. Monoclonal and Polyclonal Antibody 11.6.4. Sensor technology 11.6.5. Tandem Mass Spectroscopy 11.7. North America Endocrine Testing Market Value Share Analysis, by End User 11.8. North America Endocrine Testing Market Forecast, by End User 11.8.1. Hospitals 11.8.2. Physicians Offices 11.8.3. Health Care Centers 11.8.4. Commercial Laboratories 11.9. North America Endocrine Testing Market Value Share Analysis, by Country 11.10. North America Endocrine Testing Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Endocrine Testing Market Analysis, by Country 11.12. U.S. Endocrine Testing Market Forecast, by Test 11.12.1. Follicle stimulating hormone (FSH) 11.12.2. Human Chorionic Gonadotropin (hCG) 11.12.3. Thyroid Stimulating Hormone (TSH) 11.12.4. Dehydroepiandrosterone sulphate (DHEAS) 11.12.5. Prolactin 11.12.6. Progesterone 11.12.7. Insulin 11.12.8. Cortisol 11.12.9. Testosterone 11.12.10. Estradiol (E2) 11.12.11. Luteinizing Hormone (LH) 11.13. U.S. Endocrine Testing Market Forecast, by Technology 11.13.1. Immunoassay 11.13.2. Clinical Chemistry 11.13.3. Monoclonal and Polyclonal Antibody 11.13.4. Sensor technology 11.13.5. Tandem Mass Spectroscopy 11.14. U.S. Endocrine Testing Market Forecast, by End User 11.14.1. Hospitals 11.14.2. Physicians Offices 11.14.3. Health Care Centers 11.14.4. Commercial Laboratories 11.15. Canada Endocrine Testing Market Forecast, by Test 11.15.1. Follicle stimulating hormone (FSH) 11.15.2. Human Chorionic Gonadotropin (hCG) 11.15.3. Thyroid Stimulating Hormone (TSH) 11.15.4. Dehydroepiandrosterone sulphate (DHEAS) 11.15.5. Prolactin 11.15.6. Progesterone 11.15.7. Insulin 11.15.8. Cortisol 11.15.9. Testosterone 11.15.10. Estradiol (E2) 11.15.11. Luteinizing Hormone (LH) 11.16. Canada Endocrine Testing Market Forecast, by Technology 11.16.1. Immunoassay 11.16.2. Clinical Chemistry 11.16.3. Monoclonal and Polyclonal Antibody 11.16.4. Sensor technology 11.16.5. Tandem Mass Spectroscopy 11.17. Canada Endocrine Testing Market Forecast, by End User 11.17.1. Hospitals 11.17.2. Physicians Offices 11.17.3. Health Care Centers 11.17.4. Commercial Laboratories 11.18. North America Endocrine Testing Market Attractiveness Analysis 11.18.1. By Test 11.18.2. By Technology 11.18.3. By End User 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Endocrine Testing Market Analysis 12.1. Key Findings 12.2. Europe Endocrine Testing Market Overview 12.3. Europe Endocrine Testing Market Value Share Analysis, by Test 12.4. Europe Endocrine Testing Market Forecast, by Test 12.4.1. Follicle stimulating hormone (FSH) 12.4.2. Human Chorionic Gonadotropin (hCG) 12.4.3. Thyroid Stimulating Hormone (TSH) 12.4.4. Dehydroepiandrosterone sulphate (DHEAS) 12.4.5. Prolactin 12.4.6. Progesterone 12.4.7. Insulin 12.4.8. Cortisol 12.4.9. Testosterone 12.4.10. Estradiol (E2) 12.4.11. Luteinizing Hormone (LH) 12.5. Europe Endocrine Testing Market Value Share Analysis, by Technology 12.6. Europe Endocrine Testing Market Forecast, by Technology 12.6.1. Immunoassay 12.6.2. Clinical Chemistry 12.6.3. Monoclonal and Polyclonal Antibody 12.6.4. Sensor technology 12.6.5. Tandem Mass Spectroscopy 12.7. Europe Endocrine Testing Market Value Share Analysis, by End User 12.8. Europe Endocrine Testing Market Forecast, by End User 12.8.1. Hospitals 12.8.2. Physicians Offices 12.8.3. Health Care Centers 12.8.4. Commercial Laboratories 12.9. Europe Endocrine Testing Market Value Share Analysis, by Country 12.10. Europe Endocrine Testing Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Endocrine Testing Market Analysis, by Country 12.12. Germany Endocrine Testing Market Forecast, by Test 12.12.1. Follicle stimulating hormone (FSH) 12.12.2. Human Chorionic Gonadotropin (hCG) 12.12.3. Thyroid Stimulating Hormone (TSH) 12.12.4. Dehydroepiandrosterone sulphate (DHEAS) 12.12.5. Prolactin 12.12.6. Progesterone 12.12.7. Insulin 12.12.8. Cortisol 12.12.9. Testosterone 12.12.10. Estradiol (E2) 12.12.11. Luteinizing Hormone (LH) 12.13. Germany Endocrine Testing Market Forecast, by Technology 12.13.1. Immunoassay 12.13.2. Clinical Chemistry 12.13.3. Monoclonal and Polyclonal Antibody 12.13.4. Sensor technology 12.13.5. Tandem Mass Spectroscopy 12.14. Germany Endocrine Testing Market Forecast, by End User 12.14.1. Hospitals 12.14.2. Physicians Offices 12.14.3. Health Care Centers 12.14.4. Commercial Laboratories 12.15. U.K. Endocrine Testing Market Forecast, by Test 12.15.1. Follicle stimulating hormone (FSH) 12.15.2. Human Chorionic Gonadotropin (hCG) 12.15.3. Thyroid Stimulating Hormone (TSH) 12.15.4. Dehydroepiandrosterone sulphate (DHEAS) 12.15.5. Prolactin 12.15.6. Progesterone 12.15.7. Insulin 12.15.8. Cortisol 12.15.9. Testosterone 12.15.10. Estradiol (E2) 12.15.11. Luteinizing Hormone (LH) 12.16. U.K. Endocrine Testing Market Forecast, by Technology 12.16.1. Immunoassay 12.16.2. Clinical Chemistry 12.16.3. Monoclonal and Polyclonal Antibody 12.16.4. Sensor technology 12.16.5. Tandem Mass Spectroscopy 12.17. U.K. Endocrine Testing Market Forecast, by End User 12.17.1. Hospitals 12.17.2. Physicians Offices 12.17.3. Health Care Centers 12.17.4. Commercial Laboratories 12.18. France Endocrine Testing Market Forecast, by Test 12.18.1. Follicle stimulating hormone (FSH) 12.18.2. Human Chorionic Gonadotropin (hCG) 12.18.3. Thyroid Stimulating Hormone (TSH) 12.18.4. Dehydroepiandrosterone sulphate (DHEAS) 12.18.5. Prolactin 12.18.6. Progesterone 12.18.7. Insulin 12.18.8. Cortisol 12.18.9. Testosterone 12.18.10. Estradiol (E2) 12.18.11. Luteinizing Hormone (LH) 12.19. France Endocrine Testing Market Forecast, by Technology 12.19.1. Immunoassay 12.19.2. Clinical Chemistry 12.19.3. Monoclonal and Polyclonal Antibody 12.19.4. Sensor technology 12.19.5. Tandem Mass Spectroscopy 12.20. France Endocrine Testing Market Forecast, by End User 12.20.1. Hospitals 12.20.2. Physicians Offices 12.20.3. Health Care Centers 12.20.4. Commercial Laboratories 12.21. Italy Endocrine Testing Market Forecast, by Test 12.21.1. Follicle stimulating hormone (FSH) 12.21.2. Human Chorionic Gonadotropin (hCG) 12.21.3. Thyroid Stimulating Hormone (TSH) 12.21.4. Dehydroepiandrosterone sulphate (DHEAS) 12.21.5. Prolactin 12.21.6. Progesterone 12.21.7. Insulin 12.21.8. Cortisol 12.21.9. Testosterone 12.21.10. Estradiol (E2) 12.21.11. Luteinizing Hormone (LH) 12.22. Italy Endocrine Testing Market Forecast, by Technology 12.22.1. Immunoassay 12.22.2. Clinical Chemistry 12.22.3. Monoclonal and Polyclonal Antibody 12.22.4. Sensor technology 12.22.5. Tandem Mass Spectroscopy 12.23. Italy Endocrine Testing Market Forecast, by End User 12.23.1. Hospitals 12.23.2. Physicians Offices 12.23.3. Health Care Centers 12.23.4. Commercial Laboratories 12.24. Spain Endocrine Testing Market Forecast, by Test 12.24.1. Follicle stimulating hormone (FSH) 12.24.2. Human Chorionic Gonadotropin (hCG) 12.24.3. Thyroid Stimulating Hormone (TSH) 12.24.4. Dehydroepiandrosterone sulphate (DHEAS) 12.24.5. Prolactin 12.24.6. Progesterone 12.24.7. Insulin 12.24.8. Cortisol 12.24.9. Testosterone 12.24.10. Estradiol (E2) 12.24.11. Luteinizing Hormone (LH) 12.25. Spain Endocrine Testing Market Forecast, by Technology 12.25.1. Immunoassay 12.25.2. Clinical Chemistry 12.25.3. Monoclonal and Polyclonal Antibody 12.25.4. Sensor technology 12.25.5. Tandem Mass Spectroscopy 12.26. Spain Endocrine Testing Market Forecast, by End User 12.26.1. Hospitals 12.26.2. Physicians Offices 12.26.3. Health Care Centers 12.26.4. Commercial Laboratories 12.27. Rest of Europe Endocrine Testing Market Forecast, by Test 12.27.1. Follicle stimulating hormone (FSH) 12.27.2. Human Chorionic Gonadotropin (hCG) 12.27.3. Thyroid Stimulating Hormone (TSH) 12.27.4. Dehydroepiandrosterone sulphate (DHEAS) 12.27.5. Prolactin 12.27.6. Progesterone 12.27.7. Insulin 12.27.8. Cortisol 12.27.9. Testosterone 12.27.10. Estradiol (E2) 12.27.11. Luteinizing Hormone (LH) 12.28. Rest of Europe Endocrine Testing Market Forecast, by Technology 12.28.1. Immunoassay 12.28.2. Clinical Chemistry 12.28.3. Monoclonal and Polyclonal Antibody 12.28.4. Sensor technology 12.28.5. Tandem Mass Spectroscopy 12.29. Rest Of Europe Endocrine Testing Market Forecast, by End User 12.29.1. Hospitals 12.29.2. Physicians Offices 12.29.3. Health Care Centers 12.29.4. Commercial Laboratories 12.30. Europe Endocrine Testing Market Attractiveness Analysis 12.30.1. By Test 12.30.2. By Technology 12.30.3. By End User 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Endocrine Testing Market Analysis 13.1. Key Findings 13.2. Asia Pacific Endocrine Testing Market Overview 13.3. Asia Pacific Endocrine Testing Market Value Share Analysis, by Test 13.4. Asia Pacific Endocrine Testing Market Forecast, by Test 13.4.1. Follicle stimulating hormone (FSH) 13.4.2. Human Chorionic Gonadotropin (hCG) 13.4.3. Thyroid Stimulating Hormone (TSH) 13.4.4. Dehydroepiandrosterone sulphate (DHEAS) 13.4.5. Prolactin 13.4.6. Progesterone 13.4.7. Insulin 13.4.8. Cortisol 13.4.9. Testosterone 13.4.10. Estradiol (E2) 13.4.11. Luteinizing Hormone (LH) 13.5. Asia Pacific Endocrine Testing Market Value Share Analysis, by Technology 13.6. Asia Pacific Endocrine Testing Market Forecast, by Technology 13.6.1. Immunoassay 13.6.2. Clinical Chemistry 13.6.3. Monoclonal and Polyclonal Antibody 13.6.4. Sensor technology 13.6.5. Tandem Mass Spectroscopy 13.7. Asia Pacific Endocrine Testing Market Value Share Analysis, by End User 13.8. Asia Pacific Endocrine Testing Market Forecast, by End User 13.8.1. Hospitals 13.8.2. Physicians Offices 13.8.3. Health Care Centers 13.8.4. Commercial Laboratories 13.9. Asia Pacific Endocrine Testing Market Value Share Analysis, by Country 13.10. Asia Pacific Endocrine Testing Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Endocrine Testing Market Analysis, by Country 13.12. China Endocrine Testing Market Forecast, by Test 13.12.1. Follicle stimulating hormone (FSH) 13.12.2. Human Chorionic Gonadotropin (hCG) 13.12.3. Thyroid Stimulating Hormone (TSH) 13.12.4. Dehydroepiandrosterone sulphate (DHEAS) 13.12.5. Prolactin 13.12.6. Progesterone 13.12.7. Insulin 13.12.8. Cortisol 13.12.9. Testosterone 13.12.10. Estradiol (E2) 13.12.11. Luteinizing Hormone (LH) 13.13. China Endocrine Testing Market Forecast, by Technology 13.13.1. Immunoassay 13.13.2. Clinical Chemistry 13.13.3. Monoclonal and Polyclonal Antibody 13.13.4. Sensor technology 13.13.5. Tandem Mass Spectroscopy 13.14. China Endocrine Testing Market Forecast, by End User 13.14.1. Hospitals 13.14.2. Physicians Offices 13.14.3. Health Care Centers 13.14.4. Commercial Laboratories 13.15. India Endocrine Testing Market Forecast, by Test 13.15.1. Follicle stimulating hormone (FSH) 13.15.2. Human Chorionic Gonadotropin (hCG) 13.15.3. Thyroid Stimulating Hormone (TSH) 13.15.4. Dehydroepiandrosterone sulphate (DHEAS) 13.15.5. Prolactin 13.15.6. Progesterone 13.15.7. Insulin 13.15.8. Cortisol 13.15.9. Testosterone 13.15.10. Estradiol (E2) 13.15.11. Luteinizing Hormone (LH) 13.16. India Endocrine Testing Market Forecast, by Technology 13.16.1. Immunoassay 13.16.2. Clinical Chemistry 13.16.3. Monoclonal and Polyclonal Antibody 13.16.4. Sensor technology 13.16.5. Tandem Mass Spectroscopy 13.17. India Endocrine Testing Market Forecast, by End User 13.17.1. Hospitals 13.17.2. Physicians Offices 13.17.3. Health Care Centers 13.17.4. Commercial Laboratories 13.18. Japan Endocrine Testing Market Forecast, by Test 13.18.1. Follicle stimulating hormone (FSH) 13.18.2. Human Chorionic Gonadotropin (hCG) 13.18.3. Thyroid Stimulating Hormone (TSH) 13.18.4. Dehydroepiandrosterone sulphate (DHEAS) 13.18.5. Prolactin 13.18.6. Progesterone 13.18.7. Insulin 13.18.8. Cortisol 13.18.9. Testosterone 13.18.10. Estradiol (E2) 13.18.11. Luteinizing Hormone (LH) 13.19. Japan Endocrine Testing Market Forecast, by Technology 13.19.1. Immunoassay 13.19.2. Clinical Chemistry 13.19.3. Monoclonal and Polyclonal Antibody 13.19.4. Sensor technology 13.19.5. Tandem Mass Spectroscopy 13.20. Japan Endocrine Testing Market Forecast, by End User 13.20.1. Hospitals 13.20.2. Physicians Offices 13.20.3. Health Care Centers 13.20.4. Commercial Laboratories 13.21. ASEAN Endocrine Testing Market Forecast, by Test 13.21.1. Follicle stimulating hormone (FSH) 13.21.2. Human Chorionic Gonadotropin (hCG) 13.21.3. Thyroid Stimulating Hormone (TSH) 13.21.4. Dehydroepiandrosterone sulphate (DHEAS) 13.21.5. Prolactin 13.21.6. Progesterone 13.21.7. Insulin 13.21.8. Cortisol 13.21.9. Testosterone 13.21.10. Estradiol (E2) 13.21.11. Luteinizing Hormone (LH) 13.22. ASEAN Endocrine Testing Market Forecast, by Technology 13.22.1. Immunoassay 13.22.2. Clinical Chemistry 13.22.3. Monoclonal and Polyclonal Antibody 13.22.4. Sensor technology 13.22.5. Tandem Mass Spectroscopy 13.23. ASEAN Endocrine Testing Market Forecast, by End User 13.23.1. Hospitals 13.23.2. Physicians Offices 13.23.3. Health Care Centers 13.23.4. Commercial Laboratories 13.24. Rest of Asia Pacific Endocrine Testing Market Forecast, by Test 13.24.1. Follicle stimulating hormone (FSH) 13.24.2. Human Chorionic Gonadotropin (hCG) 13.24.3. Thyroid Stimulating Hormone (TSH) 13.24.4. Dehydroepiandrosterone sulphate (DHEAS) 13.24.5. Prolactin 13.24.6. Progesterone 13.24.7. Insulin 13.24.8. Cortisol 13.24.9. Testosterone 13.24.10. Estradiol (E2) 13.24.11. Luteinizing Hormone (LH) 13.25. Rest of Asia Pacific Endocrine Testing Market Forecast, by Technology 13.25.1. Immunoassay 13.25.2. Clinical Chemistry 13.25.3. Monoclonal and Polyclonal Antibody 13.25.4. Sensor technology 13.25.5. Tandem Mass Spectroscopy 13.26. Rest of Asia Pacific Endocrine Testing Market Forecast, by End User 13.26.1. Hospitals 13.26.2. Physicians Offices 13.26.3. Health Care Centers 13.26.4. Commercial Laboratories 13.27. Asia Pacific Endocrine Testing Market Attractiveness Analysis 13.27.1. By Test 13.27.2. By Technology 13.27.3. By End User 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Endocrine Testing Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Endocrine Testing Market Overview 14.3. Middle East & Africa Endocrine Testing Market Value Share Analysis, by Test 14.4. Middle East & Africa Endocrine Testing Market Forecast, by Test 14.4.1. Follicle stimulating hormone (FSH) 14.4.2. Human Chorionic Gonadotropin (hCG) 14.4.3. Thyroid Stimulating Hormone (TSH) 14.4.4. Dehydroepiandrosterone sulphate (DHEAS) 14.4.5. Prolactin 14.4.6. Progesterone 14.4.7. Insulin 14.4.8. Cortisol 14.4.9. Testosterone 14.4.10. Estradiol (E2) 14.4.11. Luteinizing Hormone (LH) 14.5. Middle East & Africa Endocrine Testing Market Value Share Analysis, by Technology 14.6. Middle East & Africa Endocrine Testing Market Forecast, by Technology 14.6.1. Immunoassay 14.6.2. Clinical Chemistry 14.6.3. Monoclonal and Polyclonal Antibody 14.6.4. Sensor technology 14.6.5. Tandem Mass Spectroscopy 14.7. Middle East & Africa Endocrine Testing Market Value Share Analysis, by End User 14.8. Middle East & Africa Endocrine Testing Market Forecast, by End User 14.8.1. Hospitals 14.8.2. Physicians Offices 14.8.3. Health Care Centers 14.8.4. Commercial Laboratories 14.9. Middle East & Africa Endocrine Testing Market Value Share Analysis, by Country 14.10. Middle East & Africa Endocrine Testing Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Endocrine Testing Market Analysis, by Country 14.12. GCC Endocrine Testing Market Forecast, by Test 14.12.1. Follicle stimulating hormone (FSH) 14.12.2. Human Chorionic Gonadotropin (hCG) 14.12.3. Thyroid Stimulating Hormone (TSH) 14.12.4. Dehydroepiandrosterone sulphate (DHEAS) 14.12.5. Prolactin 14.12.6. Progesterone 14.12.7. Insulin 14.12.8. Cortisol 14.12.9. Testosterone 14.12.10. Estradiol (E2) 14.12.11. Luteinizing Hormone (LH) 14.13. GCC Endocrine Testing Market Forecast, by Technology 14.13.1. Immunoassay 14.13.2. Clinical Chemistry 14.13.3. Monoclonal and Polyclonal Antibody 14.13.4. Sensor technology 14.13.5. Tandem Mass Spectroscopy 14.14. GCC Endocrine Testing Market Forecast, by End User 14.14.1. Hospitals 14.14.2. Physicians Offices 14.14.3. Health Care Centers 14.14.4. Commercial Laboratories 14.15. South Africa Endocrine Testing Market Forecast, by Test 14.15.1. Follicle stimulating hormone (FSH) 14.15.2. Human Chorionic Gonadotropin (hCG) 14.15.3. Thyroid Stimulating Hormone (TSH) 14.15.4. Dehydroepiandrosterone sulphate (DHEAS) 14.15.5. Prolactin 14.15.6. Progesterone 14.15.7. Insulin 14.15.8. Cortisol 14.15.9. Testosterone 14.15.10. Estradiol (E2) 14.15.11. Luteinizing Hormone (LH) 14.16. South Africa Endocrine Testing Market Forecast, by Technology 14.16.1. Immunoassay 14.16.2. Clinical Chemistry 14.16.3. Monoclonal and Polyclonal Antibody 14.16.4. Sensor technology 14.16.5. Tandem Mass Spectroscopy 14.17. South Africa Endocrine Testing Market Forecast, by End User 14.17.1. Hospitals 14.17.2. Physicians Offices 14.17.3. Health Care Centers 14.17.4. Commercial Laboratories 14.18. Rest of Middle East & Africa Endocrine Testing Market Forecast, by Test 14.18.1. Follicle stimulating hormone (FSH) 14.18.2. Human Chorionic Gonadotropin (hCG) 14.18.3. Thyroid Stimulating Hormone (TSH) 14.18.4. Dehydroepiandrosterone sulphate (DHEAS) 14.18.5. Prolactin 14.18.6. Progesterone 14.18.7. Insulin 14.18.8. Cortisol 14.18.9. Testosterone 14.18.10. Estradiol (E2) 14.18.11. Luteinizing Hormone (LH) 14.19. Rest of Middle East & Africa Endocrine Testing Market Forecast, by Technology 14.19.1. Immunoassay 14.19.2. Clinical Chemistry 14.19.3. Monoclonal and Polyclonal Antibody 14.19.4. Sensor technology 14.19.5. Tandem Mass Spectroscopy 14.20. Rest of Middle East & Africa Endocrine Testing Market Forecast, by End User 14.20.1. Hospitals 14.20.2. Physicians Offices 14.20.3. Health Care Centers 14.20.4. Commercial Laboratories 14.21. Middle East & Africa Endocrine Testing Market Attractiveness Analysis 14.21.1. By Test 14.21.2. By Technology 14.21.3. By End User 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Endocrine Testing Market Analysis 15.1. Key Findings 15.2. South America Endocrine Testing Market Overview 15.3. South America Endocrine Testing Market Value Share Analysis, by Test 15.4. South America Endocrine Testing Market Forecast, by Test 15.4.1. Follicle stimulating hormone (FSH) 15.4.2. Human Chorionic Gonadotropin (hCG) 15.4.3. Thyroid Stimulating Hormone (TSH) 15.4.4. Dehydroepiandrosterone sulphate (DHEAS) 15.4.5. Prolactin 15.4.6. Progesterone 15.4.7. Insulin 15.4.8. Cortisol 15.4.9. Testosterone 15.4.10. Estradiol (E2) 15.4.11. Luteinizing Hormone (LH) 15.5. South America Endocrine Testing Market Value Share Analysis, by Technology 15.6. South America Endocrine Testing Market Forecast, by Technology 15.6.1. Immunoassay 15.6.2. Clinical Chemistry 15.6.3. Monoclonal and Polyclonal Antibody 15.6.4. Sensor technology 15.6.5. Tandem Mass Spectroscopy 15.7. South America Endocrine Testing Market Value Share Analysis, by End User 15.8. South America Endocrine Testing Market Forecast, by End User 15.8.1. Hospitals 15.8.2. Physicians Offices 15.8.3. Health Care Centers 15.8.4. Commercial Laboratories 15.9. South America Endocrine Testing Market Value Share Analysis, by Country 15.10. South America Endocrine Testing Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Endocrine Testing Market Analysis, by Country 15.12. Brazil Endocrine Testing Market Forecast, by Test 15.12.1. Follicle stimulating hormone (FSH) 15.12.2. Human Chorionic Gonadotropin (hCG) 15.12.3. Thyroid Stimulating Hormone (TSH) 15.12.4. Dehydroepiandrosterone sulphate (DHEAS) 15.12.5. Prolactin 15.12.6. Progesterone 15.12.7. Insulin 15.12.8. Cortisol 15.12.9. Testosterone 15.12.10. Estradiol (E2) 15.12.11. Luteinizing Hormone (LH) 15.13. Brazil Endocrine Testing Market Forecast, by Technology 15.13.1. Immunoassay 15.13.2. Clinical Chemistry 15.13.3. Monoclonal and Polyclonal Antibody 15.13.4. Sensor technology 15.13.5. Tandem Mass Spectroscopy 15.14. Brazil Endocrine Testing Market Forecast, by End User 15.14.1. Hospitals 15.14.2. Physicians Offices 15.14.3. Health Care Centers 15.14.4. Commercial Laboratories 15.15. Mexico Endocrine Testing Market Forecast, by Test 15.15.1. Follicle stimulating hormone (FSH) 15.15.2. Human Chorionic Gonadotropin (hCG) 15.15.3. Thyroid Stimulating Hormone (TSH) 15.15.4. Dehydroepiandrosterone sulphate (DHEAS) 15.15.5. Prolactin 15.15.6. Progesterone 15.15.7. Insulin 15.15.8. Cortisol 15.15.9. Testosterone 15.15.10. Estradiol (E2) 15.15.11. Luteinizing Hormone (LH) 15.16. Mexico Endocrine Testing Market Forecast, by Technology 15.16.1. Immunoassay 15.16.2. Clinical Chemistry 15.16.3. Monoclonal and Polyclonal Antibody 15.16.4. Sensor technology 15.16.5. Tandem Mass Spectroscopy 15.17. Mexico Endocrine Testing Market Forecast, by End User 15.17.1. Hospitals 15.17.2. Physicians Offices 15.17.3. Health Care Centers 15.17.4. Commercial Laboratories 15.18. Rest of South America Endocrine Testing Market Forecast, by Test 15.18.1. Follicle stimulating hormone (FSH) 15.18.2. Human Chorionic Gonadotropin (hCG) 15.18.3. Thyroid Stimulating Hormone (TSH) 15.18.4. Dehydroepiandrosterone sulphate (DHEAS) 15.18.5. Prolactin 15.18.6. Progesterone 15.18.7. Insulin 15.18.8. Cortisol 15.18.9. Testosterone 15.18.10. Estradiol (E2) 15.18.11. Luteinizing Hormone (LH) 15.19. Rest of South America Endocrine Testing Market Forecast, by Technology 15.19.1. Immunoassay 15.19.2. Clinical Chemistry 15.19.3. Monoclonal and Polyclonal Antibody 15.19.4. Sensor technology 15.19.5. Tandem Mass Spectroscopy 15.20. Rest of South America Endocrine Testing Market Forecast, by End User 15.20.1. Hospitals 15.20.2. Physicians Offices 15.20.3. Health Care Centers 15.20.4. Commercial Laboratories 15.21. South America Endocrine Testing Market Attractiveness Analysis 15.21.1. By Test 15.21.2. By Technology 15.21.3. By End User 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Thermo Fisher Scientific, Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Developing Footprint 16.3.2. Quest Technology 16.3.3. Biomedical Technologies. 16.3.4. Sysmex Corporation 16.3.5. Abbott Laboratories 16.3.6. AB Sciex Pte. Ltd. 16.3.7. Agilent Technologies 16.3.8. Siemens Healthcare 16.3.9. Ortho Clinical Technology 16.3.10. BioMerieux SA 16.3.11. Bio-Rad Laboratories 16.3.12. DiaSorin S.p.A 16.3.13. F. Hoffmann-La Roche Ltd. 16.3.14. Laboratory Corporation of America Holdings 16.3.15. Hoffmann-La Roche Ltd. 16.3.16. LabCorp 16.3.17. Alfa Aesar 16.3.18. Laboratory Corporation of America Holdings (LabCorp) 16.3.19. Beckman Coulter Inc 16.3.20. Teleflex Inc 17. Primary Key Insights

About This Report

Report ID 33711
Category Healthcare
Published Date Aug 2019
Updated Date Dec 2020